Skip to content
AwardedSpainGoods€2,823,840

Adquisición del medicamento BREYANZI 1,1-70 x 10E6 Células/ML dispersión para perfusión (Lisocabtagen Maraleucel), para el Servicio de Farmacia del Hospital Universitario Ramón y Cajal.

Published
Published 24 June 2026

Overview

Hospital Universitario Ramón y Cajal procured the pharmaceutical medication Breyanzi (Lisocabtagen Maraleucel) 1.1-70 x 10E6 Cells/mL dispersion for infusion for its pharmacy service. The award was granted to Bristol Myers Squibb S.A.U. on 28 May 2026 for the contract value of €2,823,840.

Key details

Country
Spain
Status
Awarded
Category
Goods
Estimated value
€2,823,840
Procedure
Direct
Published
24 June 2026
Classification (CPV)
Antineoplastic agents

Award outcome

Awarded value
€2,823,840
Award date
28 May 2026
Winner
  • BRISTOL MYERS SQUIBB S.A.U.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    24 June 2026

Contracting authority

  • HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

    Procuring entity

    Madrid, Spain

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Adquisición del medicamento BREYANZI 1,1-70 x 10E6 Células/ML dispersión para perfusión (Lisocabtagen Maraleucel), para el Servicio de Farmacia del Hospital Universitario Ramón y Cajal. — won by BRISTOL MYERS SQUIBB S.A.U. — Skim